Apures Co (XKRX:149300) Debt-to-Asset : 0.40 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Apures Co Debt-to-Asset?

Apures Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩3,610.4 Mil. Apures Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩2,632.0 Mil. Apures Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was ₩15,624.9 Mil. Apures Co's debt to asset for the quarter that ended in Dec. 2023 was 0.40.

Apures Co Debt-to-Asset Historical Data

The historical data trend for Apures Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apures Co Debt-to-Asset Chart

Apures Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.32

0.54

0.37

0.44

0.40

Apures Co Semi-Annual Data
	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Debt-to-Asset	Get a 7-Day Free Trial					0.32	0.54	0.37	0.44	0.40

Competitive Comparison of Apures Co's Debt-to-Asset

For the Diagnostics & Research subindustry, Apures Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apures Co's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Apures Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Apures Co's Debt-to-Asset falls into.

Apures Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Apures Co's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3610.362	+	2632.019)	/	15624.916
	=	0.40

Apures Co's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3610.362	+	2632.019)	/	15624.916
	=	0.40

Apures Co (XKRX:149300) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Apures Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Apures Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Apures Co (XKRX:149300) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Apures Co Ltd (XKRX:149300) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

44, Hansan-gil, Cheongbuk-eup, Gyeonggi-do, Pyeongtaek-si, KOR, 17792

Website

http://www.apures.com

Apures Co Ltd is a South Korea based company engaged in the development of transgenic animals to support bio heterogeneous long-term commercialization and new drug efficacy research. It has focused its research capabilities on developing transgenic mini pigs based on gene editing technology and somatic cell nuclear transfer technology.

Apures Co (XKRX:149300) Headlines

No Headlines